IXP Lifesciences Launches INR 200 Cr Fund for Biotech Innovation

Reportedly, the lifesciences fund seeks to build a portfolio of 20-25 companies, investing in pharmaceuticals, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals.

IXP, a life sciences-focused venture capital firm backed by JV Ventures, plans to raise INR 200 Cr through its first fund to invest in early-stage companies.

The IXP Lifesciences Catalyst Fund will focus on business-to-business (B2B) startups from pre-seed to Series A stages. It includes a greenshoe option of INR 100 Cr and aims for an investment horizon of three to five years, targeting an internal rate of return (IRR) of 22% or higher.

Reportedly, the lifesciences fund seeks to build a portfolio of 20-25 companies, investing in pharmaceuticals, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals.

Sharing thoughts, Ketki Tulpule, CIO at IXP said., “IXP was born out of a need we saw in the Indian start-up ecosystem. In fact, we conducted a pan-India survey to understand the pain points of biotech’s for an outside-in perspective. The sector is nuanced, and requires investors with scientific expertise, industry knowledge, and operational experience to help biotech’ssucceed. We are glad to have onboarded industry veterans as council members and advisors who add to the scientific heft of the fund”

“The Indian Lifesciences industry is dynamic with large untapped potential. Through IXP Venture Studio, we will co-create companies along with scientists for ideas addressing unmet needs in the market. Unlike traditional VCs, IXP has a hands-on approach through active participation from concept to scale. The Ventureprenuer Program has been designed to transform scientists into founders”, Vishal Goel, Partner at IXP and cofounder of JV Ventures, added.

While according to Jasmeet Chhabra, Partner at IXP and Co-founder of JV Ventures, “The success of biotech’s hinges on many factors, not just capital. These early-stage companies require access to larger ecosystems for laboratories, networks and R&D services which we provide through PoweRx, the Lifesciences vertical of JV Ventures. This differentiates IXP from other funds as it leverages synergies within the group to create a winning proposition for portfolio companies.”

With this move, IXP aims to support scientists and innovators by integrating them into the lifesciences ecosystem.

Stay tuned for more such updates on Digital Health News.